Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism

NCT03941236 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.

NCT NCT03941236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
Lead sponsor
Zealand Pharma
Phase
Phase 3
Overall status
Completed
Start date
May 2, 2019
Completion date
May 26, 2026
Enrollment
42 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

congenital hyperinsulinism